Can Metformin Use Cut Wet AMD Risk?

Maria Berrocal, MD and Dimitra Skondra, MD, PhD

Show Description +

Could metformin reduce risk of wet AMD development? Maria Berrocal, MD, speaks with Dimitra Skondra, MD, PhD, about a study published in Ophthalmology Retina finding that metformin exposure was associated with up to 30% lower odds of new-onset wet AMD. They discuss what the findings mean for patients with and without diabetes, where the protective effect appears to break down, and what a prospective trial could tell us next.

Posted: 9/28/2026

Keywords:

Metformin

•

Wet AMD

•

Diabetes

Up Next

Name: Can Metformin Use Cut Wet AMD Risk?
Uploaded: 2026-09-28T16:44:33+00:00

Does Preoperative Anti-VEGF Change Outcomes in Non-Tractional Vitreous Hemorrhage?

Maria Berrocal, MD and Sumit Sharma, MD

Secondary IOL Surgery Is Unprofitable Under Current Medicare Reimbursement Rates. Now What?

Maria Berrocal, MD and Nimesh "Nemo" Patel, MD

Socioeconomic Determinants and Outcomes in Proliferative Sickle Retinopathy

Maria Berrocal, MD and Audina Berrocal, MD

Vitreous Sensing Vitrectomy

Maria Berrocal, MD and Jordan Deaner, MD

New Methotrexate Protocol in RD Repair in High-Risk PVR Cases

Maria Berrocal, MD and Maggie Runner, MD

Trends in PDR Treatments

Maria Berrocal, MD; and Katherine Talcott, MD

MH Risk Factors After RRD Repair

Maria Berrocal, MD and Avni Finn, MD

Real-World Switching to Faricimab from Legacy Anti-VEGFs in Wet AMD

Maria Berrocal, MD and Lejla Vajzovic, MD

Suprachoroidal Steroids in Patients With a History of Glaucoma and Ocular Hypertension

Maria Berrocal, MD and Danny Mammo, MD

Anti-VEGF for Proliferative Sickle Cell Retinopathy

Maria Berrocal, MD and Jennifer Lim, MD

Can LLMs Conduct Human-level Research?

Maria Berrocal, MD; Ariel Ong, MD; and David Merle, MD

ILM Peeling for Small Macular Hole

Maria Berrocal, MD and Francesco Boscia, MD

RRDs After Macular Surgery

Maria Berrocal, MD and J. Fernando Arevalo, MD, PhD

AI for Ocular Oncology

Maria Berrocal, MD and Zelia Correa, MD, PhD

TKIs and the Future of Care

Maria Berrocal, MD and Dilsher Dhoot, MD

Late-Presenting IOFBs: How To Detect Them—and Why They Are Missed

Maria Berrocal, MD and Nimesh Patel, MD

AI Chatbots vs. Ophthalmology Trainees for Diagnosing and Triaging Common Conditions

Maria H. Berrocal, MD and Sruthi Arepalli, MD

Growing Comfortable with the Suprachoroidal Space

Maria Berrocal, MD, and Robert L. Avery, MD

Update on Predatory "Cell Therapy" Clinics

María H. Berrocal, MD and Ajay Kuriyan, MD

Is Teleretinal Screening for DR and DME Effective?

María H. Berrocal, MD; and Christina Y. Weng, MD, MBA

Drs. Berrocal and Chaudhry discuss the limitations of meta-analysis in ophthalmology research.

Maria Berrocal, MD, and Varun Chaudhry, MD

Clinical Minute: Retina: Features Associated with Progression to GA in AMD

Maria Berrocal, MD, and Usha Chakravarthy, MD, PhD

Clinical Minute: Retina: Simultaneous UWF Imaging with OCT and FFA/ICGA

Paulo E. Stanga, MD, and Maria H. Berrocal, MD

Clinical Minute: Retina: AI in ROP

María Berrocal, MD and Darius Moshfeghi, MD

Clinical Minute: Retina: The Mac Tel Project

María Berrocal, MD and Lihteh Wu, MD

Clinical Minute: Retina: The Future of the PDS with Ranibizumab

Dante Pieramici, MD and María Berrocal, MD

Clinical Minute Retina: PPV for VH Secondary to RVO

Ramin Tadayoni, MD, PhD and Carl Regillo, MD

GATHER2 Data at 1 and 2 Years

Ramin Tadayoni, MD, PhD and Arshad Khanani, MD, MA

Response to Protocol V: Is Observation a Wise Approach to DME with 20/25 Vision?

Diana Do, MD, and Ramin Tadayoni, MD, PhD

Baseline Characteristics and Response to Intravitreal Dexamethasone Implant in DME

Patricia Udaondo, MD, PhD and Ramin Tadayoni, MD, PhD

Biosimilars in Retina

Ramin Tadayoni, MD, PhD, and Prof. Frank Holz

Meta-analysis of Anti-VEGF Agents in Wet AMD Therapy

Ramin Tadayoni, MD, PhD and Jean-Francois Korobelnik, MD, PhD

PPV vs Conventional Therapy for PDR

María H. Berrocal, MD, and Ramin Tadayoni, MD, PhD

ALOFT Study: Value of False Positive Alerts in Home Monitoring for Wet AMD Conversion

Ramin Tadayoni, MD, PhD, and Allen C. Ho, MD

GA Therapy After the Newest DERBY/OAKS Data

Eleonora Lad, MD, PhD and Ramin Tadayoni, MD, PhD

Protocol AC: Step Therapy in DME

Chirag D. Jhaveri, MD; and Prof. Ramin Tadayoni

TRUCKEE Study Data

Ramin Tadayoni, MD, PhD and Arshad Khanani, MD, MA

Pegcetacoplan Phase 3 Data

Ramin Tadayoni, MD, PhD and Caroline Baumal, MD

Rates of Endophthalmitis in a Nationwide Study

Ramin Tadayoni, MD, PhD; and Catherine Creuzot-Garcher, MD

Why Some Clinical Trials Succeed Where Others Do Not

Ramin Tadayoni, MD, PhD; and Peter Kaiser, MD

AI in Retinal Imaging

Ramin Tadayoni, MD, PhD; Ursula Schmidt-Erfurth, MD

Intraoperative OCT: From Concept to Execution

Ramin Tadayoni, MD, PhD; and Cynthia Toth, MD

AI in the Modern Age of Retina

Anat Loewenstein MD, MHA

The History of ILM Staining

Ramin Tadayoni MD, PhD; and Kazuaki Kadonosono, MD, PhD

Phase 3 Faricimab Data and the Dawn of a New Molecule

Ramin Tadayoni, MD, PhD and Charles Wykoff, MD, PhD

Back to All Videos

Can Metformin Use Cut Wet AMD Risk?

Maria Berrocal, MD and Dimitra Skondra, MD, PhD

Posted: 9/28/2026

Keywords:

Metformin

•

Wet AMD

•

Diabetes

Please log in to leave a comment.

Series:

Clinical Minute Retina

Can Metformin Use Cut Wet AMD Risk?

Up Next

Can Metformin Use Cut Wet AMD Risk?

Related Videos